Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-4362.2003.01962.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: We sought to compare the safety and efficacy of combining fractional 2940-nm Erbium:YAG (Er:YAG) laser with autologous platelet-rich plasma (PRP) versus its combination with low-level laser therapy (LLLT) for enhancing the outcome of postsurgical and post-traumatic scars.
Methods: Fourty-five individuals with post-surgical or post-traumatic scars were randomly divided into three groups: Group A received four fractional Er:YAG laser sessions spaced four weeks apart along with eight sessions of intradermal PRP injections spaced two weeks apart; Group B received four fractional Er:YAG laser sessions spaced four weeks apart along with two sessions of light emitting diode (LED) weekly; and Group C received four fractional Er:YAG laser sessions spaced four weeks apart. Treatment efficacy was evaluated using clinical photographs, Vancouver Scar Scale (VSS), patient satisfaction and histopathology.
Enhancing glioblastoma therapy via intranasal administration of highly potent cell-penetrating peptide decorated nanoparticles.
J Control Release
January 2025
Department of Global Innovative Drugs, The Graduate School of Chung-Ang University, 221 Heukseok-dong, Dongjak-gu, Seoul 06974, Republic of Korea; College of Pharmacy, Chung-Ang University, 221 Heukseok-dong, Dongjak-gu, Seoul 06974, Republic of Korea. Electronic address:
Glioblastoma multiforme (GBM) is a devastating primary tumor of the central nervous system with a significantly poor prognosis. The primary challenge in treating GBM lies in the restrictive nature of the blood-brain barrier (BBB), impeding effective drug delivery to the brain. In this study, intranasal polymeric micelles encapsulating a quercetin-etoposide combination were developed to induce synergistic apoptotic effects and enhance direct drug delivery to the brain.
View Article and Find Full Text PDFEnhancing transdermal delivery of chrysomycin A for the treatment of cutaneous melanoma and MRSA infections using Skin-Penetrating Peptide-Functionalized deformable liposomes.
Int J Pharm
December 2024
Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals & College of Pharmaceutical Science, Zhejiang University of Technology, 310014 Hangzhou, China; Zhejiang Key Laboratory of Green, Low-carbon and Efficient Development of Marine Fishery Resources, Hangzhou 310014, China. Electronic address:
Article Synopsis
- Transdermal drug delivery using SPACE-modified liposomal chrysomycin A (CA@SPACE-LP) shows promise for treating skin diseases like melanoma and MRSA infections.
- In vitro studies reveal that CA@SPACE-LP significantly enhances drug penetration into skin layers, achieving a threefold increase in intradermal drug concentration compared to free chrysomycin A.
- In vivo results indicate that CA@SPACE-LP effectively suppresses melanoma tumor growth by about 60% and outperforms conventional treatments for MRSA, suggesting its potential for combined cancer and infection therapy.
Clinical Study of Intradermal Injection of Non-Crosslinked Sodium Hyaluronate Combined With Human Epidermal Growth Factor in the Treatment of Skin Barrier Injury in Plateau Area.
J Cosmet Dermatol
December 2024
Department of Plastic Surgery, Affiliated Calmette Hospital of Kunming Medical University, Kunming, China.
Background: The Yunnan-Guizhou Plateau's high-altitude setting is characterized by intense solar ultraviolet radiation, a significant environmental stressor that frequently leads to skin barrier damage. This damage presents clinically as erythema, itching, and desquamation, underscoring the need for effective reparative interventions.
Aims: The objective of this study was to assess the therapeutic efficacy of a novel treatment protocol that integrates non-crosslinked hyaluronic acid (HA) injection with microneedle application of human epidermal growth factor (hEGF) for the restoration of skin barrier function in regions of high altitude.
Advanced transdermal drug delivery system: A comprehensive review of microneedle technologies, novel designs, diverse applications, and critical challenges.
Int J Pharm
December 2024
Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.
Transdermal drug delivery presents numerous advantages over conventional administration routes, including non-invasiveness, enhanced patient adherence, circumvention of hepatic first-pass metabolism, self-administration capabilities, controlled release, and increased bioavailability. Nevertheless, the barrier function of stratum corneum limits this strategy to molecules possessing requisite physicochemical attributes. To expand the field of transdermal delivery, researchers have pioneered physical enhancement techniques, with micron-sized needles emerging as a particularly promising platform for the transdermal and intradermal delivery of therapeutic agents across a spectrum of molecular sizes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!